

Nicola Normanno

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5821405/nicola-normanno-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

262
papers

15,771
citations

58
h-index

120
g-index

280
ext. papers

18,020
ext. citations

5.5
avg, IF

6.18
L-index

#	Paper	IF	Citations
262	Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	4
261	Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.. <i>Oncologist</i> , 2022 , 27, 7-12	5.7	0
260	Delivering precision oncology to patients with cancer.. <i>Nature Medicine</i> , 2022 , 28, 658-665	50.5	7
259	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022 , 7, 100459	6	1
258	The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies.. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 169, 103567	7	13
257	Skin Toxicity as Predictor of Survival in Refractory Patients with Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy. <i>Cancers</i> , 2021 , 13,	6.6	2
256	Isochorismatase domain-containing protein 1 (ISOC1) participates in DNA damage repair and inflammation-related pathways to promote lung cancer development. <i>Translational Lung Cancer Research</i> , 2021 , 10, 1444-1456	4.4	1
255	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. <i>European Journal of Cancer</i> , 2021 , 146, 30-47	7.5	15
254	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021 , 10, 1653-1665	4.4	2
253	Promising Role of Circulating Tumor Cells in the Management of SCLC. <i>Cancers</i> , 2021 , 13,	6.6	1
252	Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 1	5.1	0
251	Challenges in bioinformatics approaches to tumor mutation burden analysis. <i>Oncology Letters</i> , 2021 , 22, 555	2.6	0
250	Angiogenesis Inhibitors in Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 655316	5.3	6
249	SARS-CoV-2 complete genome sequencing from the Italian Campania region using a highly automated next generation sequencing system. <i>Journal of Translational Medicine</i> , 2021 , 19, 246	8.5	5
248	COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC). <i>ESMO Open</i> , 2021 , 6, 100165	6	3
247	The International Collaboration for Cancer Classification and Research. <i>International Journal of Cancer</i> , 2021 , 148, 560-571	7.5	9
246	Surgery in Small-Cell Lung Cancer. <i>Cancers</i> , 2021 , 13,	6.6	4

245	Cell-free DNA from cerebrospinal fluid can be used to detect the mutation status of lung adenocarcinoma patients with central nervous system metastasis. <i>Translational Lung Cancer Research</i> , 2021 , 10, 914-925	4.4	2
244	Validation of a Targeted Next-Generation Sequencing Panel for Tumor Mutation Burden Analysis: Results from the Onconetwork Immuno-Oncology Consortium. <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 882-893	5.1	0
243	Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. <i>JAMA Oncology</i> , 2021 , 7, 1529-1535	13.4	13
242	Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems. <i>Seminars in Cancer Biology</i> , 2021 ,	12.7	3
241	The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 165, 103436	7	28
240	Molecular tests and target therapies in oncology: recommendations from the Italian workshop. <i>Future Oncology</i> , 2021 , 17, 3529-3539	3.6	6
239	RET Inhibitors in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5
238	The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC. <i>Lung Cancer</i> , 2021 , 160, 118-126	5.9	2
237	Evolution of RAS testing over time: factors influencing mutation rates in metastatic colorectal cancer patients. <i>Colorectal Cancer</i> , 2020 , 9, CRC14	0.8	2
236	The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 775-783	4.1	1
235	Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 270-276	3.8	
234	Targeted sequencing analysis of cell-free DNA from metastatic non-small-cell lung cancer patients: clinical and biological implications. <i>Translational Lung Cancer Research</i> , 2020 , 9, 61-70	4.4	6
233	Molecular and Genomic Profiling of Lung Cancer in the Era of Precision Medicine: A Position Paper from the Italian Association of Thoracic Oncology (AIOT). <i>Cancers</i> , 2020 , 12,	6.6	4
232	External Quality Assessment Schemes for Biomarker Testing in Oncology: Comparison of Performance between Formalin-Fixed, Paraffin-Embedded-Tissue and Cell-Free Tumor DNA in Plasma. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 736-747	5.1	1
231	Exploration of Targeted Anti-tumor Therapy: a contribution to the development of targeted therapies 2020 , 1, 1-2		
230	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma 2020 , 1, 53-70		2
229	Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer 2020 , 1, 117-130		
228	Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study. <i>Cancers</i> , 2020 , 12,	6.6	11

227	FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	31
226	Circulating Tumor DNA Testing Opens New Perspectives in Melanoma Management. <i>Cancers</i> , 2020 , 12,	6.6	11
225	cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?. <i>EBioMedicine</i> , 2020 , 57, 102886	8.8	1
224	Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association. <i>ESMO Open</i> , 2020 , 5, e001001	6	3
223	Study of Ras Mutations Prognostic Value in Metastatic Colorectal Cancer: STORIA Analysis. <i>Cancers</i> , 2020 , 12,	6.6	6
222	Immunotherapy in Small Cell Lung Cancer. <i>Cancers</i> , 2020 , 12,	6.6	19
221	Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls. <i>Cancers</i> , 2020 , 12,	6.6	13
220	Pembrolizumab in lung cancer: current evidence and future perspectives. <i>Future Oncology</i> , 2019 , 15, 3327-3336	3.6	4
219	Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib. <i>Cancers</i> , 2019 , 11,	6.6	4
218	Implementing TMB measurement in clinical practice: considerations on assay requirements. <i>ESMO Open</i> , 2019 , 4, e000442	6	136
217	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 140, 67-72	7	40
216	Genomic Profiling of Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents. <i>Cancers</i> , 2019 , 11,	6.6	14
215	Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2019 , 4, e000498	6	27
214	IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019 , 474, 681-689	5.1	22
213	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 845-855	6.1	30
212	The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Cancers</i> , 2019 , 11,	6.6	27
211	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019 , 153, 535-540	4.9	14
210	Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. <i>Molecular Oncology</i> , 2019 , 13, 1827-1835	7.9	21

209	The potential of monitoring treatment response in non-small cell lung cancer using circulating tumour cells. <i>Expert Review of Molecular Diagnostics</i> , 2019 , 19, 683-694	3.8	9
208	Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019 , 240, 220-225	2.4	13
207	Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF- β and miRNA21 cooperation. <i>PLoS ONE</i> , 2019 , 14, e0219597	3.7	16
206	Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019 , 9,	3.8	3
205	Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives. <i>Journal of Thoracic Disease</i> , 2019 , 11, S113-S126	2.6	26
204	Circulating free tumor-derived DNA to detect mutations in patients with advanced NSCLC: French subset analysis of the ASSESS study. <i>Journal of Thoracic Disease</i> , 2019 , 11, 1370-1378	2.6	8
203	Circulating Tumor Cells and ctDNA in NSCLC 2019 , 465-475		
202	The role of circulating free DNA in the management of NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 19-28	3.5	17
201	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , 2018 , 3, e000299	6	24
200	Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe. <i>Journal of Molecular Diagnostics</i> , 2018 , 20, 483-494	5.1	19
199	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. <i>Cancer Treatment Reviews</i> , 2018 , 70, 1-8	14.4	84
198	International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA. <i>BMC Cancer</i> , 2018 , 18, 804	4.8	25
197	Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 891-900	5.5	14
196	Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. <i>BMC Cancer</i> , 2018 , 18, 828	4.8	15
195	RANTES and IL-6 cooperate in inducing a more aggressive phenotype in breast cancer cells. <i>Oncotarget</i> , 2018 , 9, 17543-17553	3.3	18
194	Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. <i>Translational Lung Cancer Research</i> , 2018 , 7, 668-677	4.4	40
193	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). <i>Oncotarget</i> , 2018 , 9, 17554-17563	3.3	16
192	Phase III study with FOLFIRI+ cetuximab versus FOLFIRI+ cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. <i>Future Oncology</i> , 2018 , 14, 1339-1346	3.6	3

191	FGFR-targeted therapeutics for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 303-311	5.9	21
190	Targeting the EGFR T790M mutation in non-small-cell lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 159-165	6.4	21
189	Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017 , 8, 12501-12516	3.3	90
188	VEGF as a potential target in lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017 , 21, 959-966	6.4	85
187	External quality assessment for EGFR mutations in Italy: improvements in performances over the time. <i>ESMO Open</i> , 2017 , 2, e000160	6	8
186	EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. <i>Lung Cancer</i> , 2017 , 113, 37-44	5.9	70
185	Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. <i>ESMO Open</i> , 2017 , 2, e000132	6	41
184	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). <i>ESMO Open</i> , 2017 , 2, e000147	6	28
183	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. <i>ESMO Open</i> , 2017 , 2, e000177	6	19
182	Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers survey. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 471, 809-813	5.1	10
181	Heterogeneity in the colorectal primary tumor and the synchronous resected liver metastases prior to and after treatment with an anti-EGFR monoclonal antibody. <i>Molecular and Clinical Oncology</i> , 2017 , 7, 113-120	1.6	12
180	Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017 , 470, 5-20	5.1	62
179	Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017 , 6, 486-498	4.4	23
178	Angiogenesis Inhibitors in NSCLC. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	41
177	Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS810-TPS810	2.2	2
176	Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells. <i>Oncotarget</i> , 2017 , 8, 42926-42938	3.3	16
175	Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 97, 143-51	7	22
174	Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. <i>Journal of Translational Medicine</i> , 2016 , 14, 61	8.5	35

173	BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. <i>Cancer Biology and Therapy</i> , 2016 , 17, 840-8	4.6	16
172	The prognostic role of circulating tumor cells in lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 859-67	3.5	16
171	RAS testing in metastatic colorectal cancer: advances in Europe. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016 , 468, 383-96	5.1	23
170	Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. <i>Annals of Oncology</i> , 2016 , 27, 1055-1061	10.3	49
169	Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. <i>Oncotarget</i> , 2016 , 7, 66595-66605	3.3	67
168	Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2016 , 99, 31-7	5.9	25
167	Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells. <i>Journal of Cellular Physiology</i> , 2016 , 231, 1514-21	7	29
166	Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. <i>Future Oncology</i> , 2016 , 12, 2071-5	3.6	18
165	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1386-422	10.3	1683
164	BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016 , 17, 461-465	4.9	27
163	Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site. <i>Cancer Biology and Therapy</i> , 2016 , 17, 1089-1093	4.6	3
162	ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1682-9	8.9	127
161	Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires (Ferra dei Fuochi) of Southern Italy. <i>Anticancer Research</i> , 2016 , 36, 2119-24	2.3	4
160	Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1177-85	5.5	8
159	Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. <i>BMC Cancer</i> , 2015 , 15, 26	4.8	42
158	Genomics driven-oncology: challenges and perspectives. <i>BMC Cancer</i> , 2015 , 15, 141	4.8	5
157	EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 438-45	8.9	115
156	Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. <i>Annals of Oncology</i> , 2015 , 26, 1710-4	10.3	101

155	Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients. <i>Pharmacogenomics</i> , 2015 , 16, 1135-48	2.6	26
154	External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. <i>Oncologist</i> , 2015 , 20, 257-62	5.7	35
153	The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences. <i>Journal of Translational Medicine</i> , 2015 , 13, 287	8.5	14
152	EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2015 , 116, 2778-85	4.7	30
151	EGFR mutations in lung cancer: from tissue testing to liquid biopsy. <i>Future Oncology</i> , 2015 , 11, 1611-23	3.6	70
150	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2015 , 21, 4153-64	12.9	13
149	Structure-fluctuation-function relationships of seven pro-angiogenic isoforms of VEGFA, important mediators of tumorigenesis. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015 , 1854, 410-25	4	11
148	Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma. <i>PLoS ONE</i> , 2015 , 10, e0139264	3.7	18
147	Vandetanib as a potential treatment for breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 1295-303	5.9	8
146	Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib. <i>Cell Cycle</i> , 2014 , 13, 148-56	4.7	37
145	Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. <i>Annals of Oncology</i> , 2014 , 25, 1756-1761	10.3	91
144	Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. <i>British Journal of Cancer</i> , 2014 , 111, 413-20	8.7	36
143	Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer. <i>Journal of Molecular Diagnostics</i> , 2014 , 16, 371-7	5.1	20
142	Treatment of small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 91, 257-70	7	49
141	KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting. <i>PLoS ONE</i> , 2014 , 9, e85897	3.7	10
140	Guidance for laboratories performing molecular pathology for cancer patients. <i>Journal of Clinical Pathology</i> , 2014 , 67, 923-31	3.9	128
139	ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1470-6	8.9	19
138	Prognostic value of circulating tumor cellsProduction in patients with extensive small-cell lung cancer. <i>Lung Cancer</i> , 2014 , 85, 314-9	5.9	50

137	Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel 2014 ,		4
136	RNA-seq analysis reveals significant effects of EGFR signalling on the secretome of mesenchymal stem cells. <i>Oncotarget</i> , 2014 , 5, 10518-28	3.3	13
135	Quercetin-3-methyl ether inhibits lapatinib-sensitive and -resistant breast cancer cell growth by inducing G(2)/M arrest and apoptosis. <i>Molecular Carcinogenesis</i> , 2013 , 52, 134-43	5	29
134	Right-sided rhabdoid colorectal tumors might be related to the serrated pathway. <i>Diagnostic Pathology</i> , 2013 , 8, 31	3	18
133	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 1207-18	3.5	10
132	Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 407-20	3.5	14
131	Guideline on the requirements of external quality assessment programs in molecular pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013 , 462, 27-37	5.1	59
130	Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. <i>Journal of Cellular Biochemistry</i> , 2013 , 114, 514-24	4.7	46
129	Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. <i>Journal of Cellular Biochemistry</i> , 2013 , 114, 1135-44	4.7	27
128	Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?. <i>Cancer Treatment Reviews</i> , 2013 , 39, 489-97	14.4	25
127	Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer. <i>Oncology Reports</i> , 2013 , 29, 1763-8	3.5	46
126	Pharmacokinetic evaluation of capecitabine in breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 225-35	5.5	8
125	Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 773-8	8.9	18
124	European consensus conference for external quality assessment in molecular pathology. <i>Annals of Oncology</i> , 2013 , 24, 1958-63	10.3	32
123	Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology. <i>BioMed Research International</i> , 2013 , 2013, 385087	3	27
122	The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies. <i>Cancer Biology and Therapy</i> , 2013 , 14, 1143-6	4.6	47
121	TGF- β exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. <i>Cell Death and Disease</i> , 2013 , 4, e620	9.8	87
120	The significance of a Cripto-1 positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics. <i>Cell Cycle</i> , 2013 , 12, 1450-6	4.7	19

119	Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 352-8	8.9	40
118	Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations. <i>Journal of Thoracic Oncology</i> , 2013 , 8, e59-60	8.9	14
117	Abstract 36: The OncoNetwork Consortium: A European Collaborative Research study on the development of an Ion AmpliSeq gene panel targeting hot spots in colon and lung cancers. 2013 ,		5
116	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel. <i>PLoS ONE</i> , 2013 , 8, e80478	3.7	88
115	Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer. <i>Oncotarget</i> , 2013 , 4, 1253-65	3.3	33
114	Comment on a comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens? <i>British Journal of Cancer</i> , 2012 , 107, 1791-2; author reply 1793-4	8.7	1
113	Mechanisms of action of EGFR inhibitors 2012 , 6-17		1
112	Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. <i>Journal of Cellular Biochemistry</i> , 2012 , 113, 3363-70	4.7	73
111	Prognostic factor for non-small cell lung cancer with bone metastases at the time of diagnosis. <i>Lung Cancer</i> , 2012 , 78, 168	5.9	4
110	Cetuximab in non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 163-75	3.5	16
109	Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. <i>Annals of Oncology</i> , 2012 , 23, 597-604	10.3	55
108	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16 Suppl 2, S17-27 ^{6.4}		472
107	Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. <i>International Journal of Oncology</i> , 2012 , 40, 378-84	4.4	12
106	Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBEO study. <i>Annals of Oncology</i> , 2012 , 23, 2027-2033	10.3	18
105	Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib. <i>Journal of Thoracic Oncology</i> , 2012 , 7, e27-8	8.9	8
104	Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 299-307	3.5	5
103	HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a further step toward personalized medicine for patients with colorectal cancer. <i>Cancer Discovery</i> , 2011 , 1, 472-4	24.4	27
102	A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. <i>Human Pathology</i> , 2011 , 42, 1047-52	3.7	26

101	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. <i>Lancet Oncology, The</i> , 2011 , 12, 594-603	21.7	453
100	Zoledronic acid in early-stage breast cancer. <i>Lancet Oncology, The</i> , 2011 , 12, 991	21.7	1
99	Pharmacokinetic evaluation of zoledronic acid. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 911-8	5.5	11
98	Optimizing response to gefitinib in the treatment of non-small-cell lung cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 2011 , 4, 1-9	2.1	2
97	Epithelial to mesenchymal transition by TGF β 1 induction increases stemness characteristics in primary non small cell lung cancer cell line. <i>PLoS ONE</i> , 2011 , 6, e21548	3.7	140
96	Letter to the Editor: Reply to Kobunai et al.. <i>Pharmacogenomics</i> , 2011 , 12, 309-310	2.6	1
95	EGFR-targeted therapy. <i>Experimental Cell Research</i> , 2011 , 317, 2765-71	4.2	83
94	Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. <i>Targeted Oncology</i> , 2011 , 6, 133-45	5	40
93	Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. <i>Journal of Cellular Physiology</i> , 2011 , 226, 2131-8	7	70
92	Gefitinib in non small cell lung cancer. <i>Journal of Biomedicine and Biotechnology</i> , 2011 , 2011, 815269		14
91	Expression and functional role of CRIPTO-1 in cutaneous melanoma. <i>British Journal of Cancer</i> , 2011 , 105, 1030-8	8.7	29
90	KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. <i>PLoS ONE</i> , 2011 , 6, e29146	3.7	26
89	Epigenetic silencing of peroxisome proliferator-activated receptor β is a biomarker for colorectal cancer progression and adverse patients outcome. <i>PLoS ONE</i> , 2010 , 5, e14229	3.7	65
88	Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 573; author reply 573-577	9.7	1
87	Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. <i>Pharmacogenomics</i> , 2010 , 11, 1169-79	2.6	39
86	New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1503-14	5.9	8
85	Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer. <i>Current Drug Targets</i> , 2010 , 11, 851-64	3	40
84	Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 387-96	4.4	34

83	Triple negative breast cancer: from molecular portrait to therapeutic intervention. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2010 , 20, 17-34	1.3	19
82	Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. <i>IDrugs: the Investigational Drugs Journal</i> , 2010 , 13, 636-45		14
81	Recommendations for mutational analysis of EGFR in lung carcinoma. <i>Pathologica</i> , 2010 , 102, 119-26	1.9	30
80	Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. <i>Oncologist</i> , 2009 , 14, 378-90	5.7	152
79	Prognostic applications of gene expression signatures in breast cancer. <i>Oncology</i> , 2009 , 77 Suppl 1, 2-8	3.6	18
78	Neuronal guidance protein Netrin-1 induces differentiation in human embryonal carcinoma cells. <i>Cancer Research</i> , 2009 , 69, 1717-21	10.1	14
77	Target-based therapies in breast cancer: current status and future perspectives. <i>Endocrine-Related Cancer</i> , 2009 , 16, 675-702	5.7	47
76	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 519-27	19.4	341
75	A "live" biopsy in a small-cell lung cancer patient by detection of circulating tumor cells. <i>Lung Cancer</i> , 2009 , 65, 123-5	5.9	25
74	Signal Transduction Inhibitors in the Treatment of Breast Cancer 2009 , 177-201		
73	Endocrine therapy plus zoledronic acid in premenopausal breast cancer. <i>New England Journal of Medicine</i> , 2009 , 360, 2368-9; author reply 2369-70	59.2	3
72	Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. <i>Lung Cancer</i> , 2008 , 60, 452-4	5.9	15
71	Osteoblastic metastases in non-small cell lung cancer and its possible significance. <i>Lung Cancer</i> , 2008 , 60, 146-147	5.9	8
70	Molecular biology of renal-cell carcinoma. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 30-34	1.6	1
69	Regulation of Cripto-1 signaling and biological activity by caveolin-1 in mammary epithelial cells. <i>American Journal of Pathology</i> , 2008 , 172, 345-57	5.8	20
68	Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. <i>Breast Cancer Research and Treatment</i> , 2008 , 112, 25-33	4.4	34
67	Leptin signaling in breast cancer: an overview. <i>Journal of Cellular Biochemistry</i> , 2008 , 105, 956-64	4.7	172
66	The role of the EGFR signaling in tumor microenvironment. <i>Journal of Cellular Physiology</i> , 2008 , 214, 559-67	7	280

65	Regulation of human Cripto-1 gene expression by TGF-beta1 and BMP-4 in embryonal and colon cancer cells. <i>Journal of Cellular Physiology</i> , 2008 , 215, 192-203	7	38
64	Breast and Colon Carcinomas: Detection with Plasma CRIPTO-1 2008 , 189-202		
63	Expression and prognostic significance of the EGFR in solid tumors 2008 , 210-223		1
62	AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. <i>Breast Cancer Research and Treatment</i> , 2007 , 102, 275-82	4.4	12
61	A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology. <i>Annals of Oncology</i> , 2007 , 18, 960-1	10.3	1
60	Erlotinib in pancreatic cancer: are tumor cells the (only) target?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5836-7	2.2	4
59	Methodological Issues of Clinical Research with EGFR Inhibitors. <i>Current Cancer Therapy Reviews</i> , 2007 , 3, 292-302	0.4	3
58	The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. <i>Journal of Cellular Physiology</i> , 2006 , 207, 420-7	7	113
57	Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. <i>Journal of Cellular Physiology</i> , 2006 , 208, 344-53	7	54
56	Identification of cripto-1 as a novel serologic marker for breast and colon cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 5158-64	12.9	69
55	Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. <i>British Journal of Cancer</i> , 2006 , 94, 1233-6	8.7	26
54	Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. <i>Oncologist</i> , 2006 , 11, 753-64	5.7	221
53	Epidermal growth factor receptor (EGFR) signaling in cancer. <i>Gene</i> , 2006 , 366, 2-16	3.8	1421
52	Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. <i>Endocrine-Related Cancer</i> , 2005 , 12, 721-47	5.7	214
51	Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. <i>Current Opinion in Oncology</i> , 2005 , 17, 212-7	4.2	36
50	Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trials. <i>Current Opinion in Oncology</i> , 2005 , 17, 123-9	4.2	7
49	Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma. <i>Oncogene</i> , 2005 , 24, 4094-105	9.2	61
48	Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. <i>Oncogene</i> , 2005 , 24, 5731-41	19.4	135

47	Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. <i>Journal of Cellular Physiology</i> , 2005 , 205, 355-63	7	26
46	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in breast cancer: current status and future development. <i>Frontiers in Bioscience - Landmark</i> , 2005 , 10, 2611-7	2.8	18
45	Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 928-30; author reply 930-1	2.2	8
44	Role of human cripto-1 in tumor angiogenesis. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 132-41	9.7	67
43	Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?. <i>Annals of Oncology</i> , 2005 , 16, 1709	10.3	9
42	Cripto-1: an oncofetal gene with many faces. <i>Current Topics in Developmental Biology</i> , 2005 , 67, 85-133	5.3	59
41	Modulation of epidermal growth factor receptor-positive circulating tumor cells by chemotherapy in non-small-cell lung cancer patients. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7746-8; author reply 7748	2.2	2
40	Netrin-1 regulates invasion and migration of mouse mammary epithelial cells overexpressing Cripto-1 in vitro and in vivo. <i>Journal of Cell Science</i> , 2005 , 118, 4633-43	5.3	30
39	Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. <i>Endocrine-Related Cancer</i> , 2005 , 12, 471-82	5.7	79
38	The ErbB receptors and their ligands in cancer: an overview. <i>Current Drug Targets</i> , 2005 , 6, 243-57	3	234
37	Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2035-6; author reply 2036-7	2.2	9
36	Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. <i>Journal of Cellular Physiology</i> , 2004 , 198, 31-9	7	55
35	Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Zinc Finger Inhibitor of EGFR) is independent of EGFR expression level. <i>Journal of Cellular Physiology</i> , 2004 , 198, 259-68	7	91
34	Epithelial mesenchymal transition is a characteristic of hyperplasias and tumors in mammary gland from MMTV-Cripto-1 transgenic mice. <i>Journal of Cellular Physiology</i> , 2004 , 201, 266-76	7	116
33	Role of the cripto (EGF-CFC) family in embryogenesis and cancer. <i>Growth Factors</i> , 2004 , 22, 133-9	1.6	27
32	CRIPTO-1: a novel target for therapeutic intervention in human carcinoma. <i>International Journal of Oncology</i> , 2004 , 25, 1013-20	1	9
31	Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?. <i>Anticancer Research</i> , 2004 , 24, 2985-9	2.3	6
30	Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. <i>Endocrine-Related Cancer</i> , 2003 , 10, 1-21	5.7	237

29	Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo. <i>Journal of Clinical Investigation</i> , 2003 , 112, 575-87	15.9	123
28	Aging and the hemopoietic system. <i>Critical Reviews in Oncology/Hematology</i> , 2003 , 48, S3-S12	7	22
27	Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?. <i>Journal of Cellular Physiology</i> , 2003 , 194, 13-9	7	108
26	Cripto 2003 , 330-334		
25	A Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. <i>Cancer Research</i> , 2003 , 63, 1192-7	10.1	80
24	Detection and localization of Cripto-1 binding in mouse mammary epithelial cells and in the mouse mammary gland using an immunoglobulin-cripto-1 fusion protein. <i>Journal of Cellular Physiology</i> , 2002 , 190, 74-82	7	19
23	Transforming growth factor β amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas 2002 , 21, 941		4
22	Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. <i>Annals of Oncology</i> , 2002 , 13, 65-72	10.3	197
21	Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells. <i>Molecular and Cellular Biology</i> , 2002 , 22, 2586-97	4.8	127
20	The role of EGF-related peptides in tumor growth. <i>Frontiers in Bioscience - Landmark</i> , 2001 , 6, D685-707	2.8	107
19	The role of EGF-related peptides in tumor growth. <i>Frontiers in Bioscience - Landmark</i> , 2001 , 6, d685-707	2.8	85
18	EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. <i>Annals of Oncology</i> , 2000 , 11, 319-25	10.3	25
17	Simultaneous blockage of different EGF-like growth factors results in efficient growth inhibition of human colon carcinoma xenografts. <i>Oncogene</i> , 2000 , 19, 5863-71	9.2	80
16	The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. <i>Endocrine-Related Cancer</i> , 2000 , 7, 199-226	5.7	99
15	EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. <i>International Journal of Cancer</i> , 1999 , 80, 589-94	7.5	30
14	Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. <i>Journal of Biological Chemistry</i> , 1997 , 272, 3330-5	5.4	77
13	EGF-related peptides in the pathophysiology of the mammary gland. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1997 , 2, 143-51	2.4	40
12	Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. <i>International Journal of Cancer</i> , 1997 , 73, 277-82	7.5	30

11	Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. <i>Breast Cancer Research and Treatment</i> , 1995 , 35, 293-7	4.4	73
10	The role of amphiregulin in breast cancer. <i>Breast Cancer Research and Treatment</i> , 1995 , 33, 103-14	4.4	55
9	Epidermal growth factor-related peptides and their receptors in human malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 1995 , 19, 183-232	7	2150
8	Amphiregulin anti-sense oligodeoxynucleotides inhibit growth and transformation of a human colon carcinoma cell line. <i>International Journal of Cancer</i> , 1995 , 62, 762-6	7.5	31
7	Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. <i>Breast Cancer Research and Treatment</i> , 1994 , 29, 11-27	4.4	93
6	Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. <i>British Journal of Cancer</i> , 1994 , 69, 903-10	8.7	104
5	Infection with a transforming growth factor alpha anti-sense retroviral expression vector reduces the in vitro growth and transformation of a human colon cancer cell line. <i>International Journal of Cancer</i> , 1993 , 54, 952-8	7.5	29
4	Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 1992 , 34, 272-8	7.4	7
3	Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. <i>Molecular Carcinogenesis</i> , 1992 , 6, 43-52	5	60
2	Regulation by estrogen through the 5Pflanking region of the transforming growth factor alpha gene. <i>Molecular Endocrinology</i> , 1991 , 5, 1955-63		73
1	Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. <i>Exploration of Targeted Anti-tumor Therapy</i> , 200-223	2.5	1